Healthcare, Pharma & Life Sciences

Armata Publishes Cryo-EM Atlas of Ar-KM Phage Tied to AP-PA02

Image
Armata Publishes Cryo-EM Atlas of Ar-KM Phage Tied to AP-PA02

Los Angeles – September 08, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) said a peer-reviewed paper in the Journal of Molecular Biology has mapped near-atomic resolution structures of eleven proteins in its Ar-KM bacteriophage, a Pseudomonas aeruginosa-targeting phage tied to the company's late-stage AP-PA02 program.

Researchers built atomic models of eleven structural proteins using cryo-electron microscopy

The study, titled "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage," combined cryo-electron microscopy, proteomics and bioinformatics to capture three distinct states of the Ar-KM phage particle from a single purified preparation. The paper is published as J Mol Biol. 2026 Nov 1; 438(21):169993. AP-PA02, an inhaled bacteriophage candidate, has completed Phase 2 studies in cystic fibrosis and non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection.

United Imaging Wins CE Mark for Dual Wide-Coverage CT Platform

Image
United Imaging Wins CE Mark for Dual Wide-Coverage CT Platform

Rotterdam – September 08, 2026 -- United Imaging has secured CE Mark certification for the uCT SiriuX and uCT SiriuX Ultrix, clearing what the company calls the world's first dual wide-coverage computed tomography family for commercial sale across Europe.

CE Mark Clears Twin-Ring Gantry System for European Sale

The certification covers a platform built on a Twin-Ring Gantry architecture, integrating dual-wide 16 cm Ultrix detectors with two liquid-metal-bearing X-ray tubes. The approval allows United Imaging to bring the systems into clinical use throughout the European market.

Superluminal Medicines Closes $60M Series B for Obesity Drug

Image
Superluminal Medicines Closes $60M Series B for Obesity Drug

Boston – September 08, 2026 -- Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, L.P., to fund a Phase 1 clinical trial for rare genetic forms of obesity expected to begin by the end of 2026.

New investors Deep Track Capital and Perceptive Advisors join the round

The financing includes participation from new investors Deep Track Capital and Perceptive Advisors, alongside existing backers RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

Gan & Lee, Menarini Ink EUR726M Deal for GLP-1 Obesity Drug

Image
Gan & Lee, Menarini Ink EUR726M Deal for GLP-1 Obesity Drug

Beijing – September 08, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive license agreement with Italy's Menarini Group worth up to EUR 726 million, excluding royalties, to register and commercialize its GLP-1 receptor agonist bofanglutide for obesity and overweight treatment across 39 countries.

Deal structure delivers EUR 62 million upfront with EUR 664 million in milestones

Gan & Lee will receive an upfront payment of EUR 62 million, milestone payments totaling up to EUR 664 million, and double-digit royalties on net sales in the licensed territory. Menarini takes responsibility for regulatory submissions and commercialization across the 27 EU Member States plus the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan countries.

Zinzino Group Revenue Rises 15% to SEK 282.2M in August 2026

Gothenburg – – September 08, 2026 -- Zinzino AB reported group revenue of SEK 282.2 million for August 2026, up 15% from SEK 245.9 million a year earlier, as growth in its direct-sales markets offset a sharp decline at subsidiary Faun Pharma.

Sales markets revenue climbs 16% to SEK 280.9 million in August

Zinzino's core direct-sales business generated SEK 280.9 million in August 2026, up from SEK 242.5 million in the same month last year, a 16% increase that drove the bulk of the group's top-line expansion.

Faun Pharma external sales drop to SEK 1.3 million from SEK 3.4 million

Faun Pharma's external sales fell to SEK 1.3 million in August 2026, down from SEK 3.4 million a year earlier, a decline that partially offset the stronger performance of Zinzino's sales markets and reduced the group's overall growth rate to 15% from the 16% posted by the sales markets alone.

Texas Cardiac Arrhythmia Institute First US Site for New PFA Trial

Austin – September 08, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first facility in the United States to enroll in a clinical trial evaluating a next-generation mapping and pulsed field ablation (PFA) system for patients with paroxysmal and persistent atrial fibrillation.

TCAI performs first procedure under global study leadership

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, conducted the first procedure using the new catheter system. The trial is designed to assess the safety and efficacy of the technology across both forms of atrial fibrillation, the most common cardiac arrhythmia, which affects millions of patients worldwide.

Lundbeck Presents Bexicaserin Dual-Action Data at Epilepsy Congress

Valby, Denmark – September 08, 2026 -- Lundbeck will present preclinical data at the European Epilepsy Congress in Athens showing its investigational drug bexicaserin simultaneously increases inhibitory and decreases excitatory neuronal activity in hippocampal brain tissue, a dual mechanism the company says supports broad-spectrum antiseizure potential across multiple epilepsy types.

Preclinical study links dual mode of action to broader seizure control
The data, to be shown in an oral presentation at the September 5-9 congress, indicate bexicaserin's effects in preclinical models span focal, generalized motor and absence seizures across different underlying etiologies. Researchers attribute the effects to the compound's high affinity and selectivity for the 5-HT2C receptor, where it acts as a superagonist.

BTL Launches Laser Division, Unveils EXOLASE ONE Fusion System

Image
BTL Launches Laser Division, Unveils EXOLASE ONE Fusion System

Prague – September 08, 2026 -- BTL has formally established a dedicated laser division and confirmed the upcoming launch of EXOLASE ONE®, a system it describes as the first medical application of fused erbium laser technology, treating an entire face in under 10 minutes.

BTL creates sixth core division to house new laser technology

The laser unit becomes BTL's sixth main division, joining existing operations in aesthetics, mental wellness, rehabilitation, cardiology and robotics. The move marks a structural expansion for the medical and aesthetic technology group as it pushes into a new laser hardware category.

BTL Launches Laser Division, Unveils EXOLASE ONE Fusion Erbium System

Image
BTL Launches Laser Division, Unveils EXOLASE ONE Fusion Erbium System

Prague – September 08, 2026 -- BTL has established a dedicated laser division and will launch its flagship EXOLASE ONE system, the first medical application of fused erbium laser technology, marking the company's sixth core business line.

EXOLASE ONE merges multiple erbium wavelengths into a single beam

The system combines several erbium laser wavelengths into one light beam, treating the same tissue location simultaneously. BTL states this creates a new form of laser-tissue interaction that overcomes prior limitations in clinical efficacy, treatment speed and patient comfort for facial rejuvenation lasers.

Clinical researcher reports full-face treatment in under 10 minutes

Dr. Reha Yavuzer, one of the first clinical researchers on the platform, said the technology covers treatment areas that typically require multiple ablative and non-ablative systems, condensing the procedure into a full-face treatment completed in under 10 minutes.

Insilico Medicine Joins HKEX Tech 100 Index Amid Record AI Drug Pipeline

Cambridge – September 08, 2026 -- Insilico Medicine (HKEX: 3696) will join the HKEX Tech 100 Index effective September 08, 2026, following methodology changes announced September 08, 2026, that widen the benchmark's exposure to the AI value chain. Index changes take effect after market close on September 08, 2026 (Friday).

HKEX Tech 100 Index tracks 100 leading Hong Kong tech names across six themes

The index measures 100 of the largest Hong Kong-listed companies with high exposure to technology themes eligible for Southbound Stock Connect. It spans artificial intelligence, biotech and pharmaceutical, electric vehicles and smart driving, information technology, internet, and robotics.